Colorectal Cancer Treatment Delay Thresholds and Metastasis Risk
-
By
-
Chi M. Nguyen
-
Todd C. Skaar
-
Thomas F. Imperiale
-
Travis S. Johnson
-
Patrick O. Monahan
-
Anita A. Turk
-
Mai P. Nguyen
-
July 14, 2026
Clinical Scorecard: Thresholds for Delaying Treatment in Colorectal Cancer and Associated Metastatic Risks
At a Glance
| Category | Detail |
|---|
| Condition | Colorectal Cancer (CRC) |
| Key Mechanisms | Delays in treatment initiation may lead to increased metastatic risk and higher healthcare costs. |
| Target Population | Patients aged 40 years or older with newly diagnosed nonmetastatic colorectal cancer (non-mCRC). |
| Care Setting | Oncology care pathways for colorectal cancer treatment. |
Key Highlights
- Timely treatment initiation is critical for nonmetastatic CRC management.
- Delays in treatment can lead to increased metastatic risks and complex care.
- The study evaluates the association between time-to-treatment initiation and 3-year metastasis risk.
- Cohort study utilized a large national claims database for analysis.
- Treatment pathways included surgery, neoadjuvant therapy, and adjuvant therapy.
Guideline-Based Recommendations
Diagnosis
- Use ICD-10-CM codes for identifying new CRC cases.
Management
- Follow stage-specific therapeutic recommendations for CRC.
Monitoring & Follow-up
- Monitor time-to-treatment initiation and its impact on metastasis risk.
Risks
- Delays in treatment initiation are associated with increased risk of metastasis.
Patient & Prescribing Data
Patients with incident non-mCRC diagnosed between January 2017 and December 2021.
Patients underwent curative-intent surgery within 1 year of diagnosis.
Clinical Best Practices
- Ensure timely treatment initiation to reduce metastatic risk.
- Utilize established coding algorithms for accurate diagnosis and treatment tracking.
- Consider treatment sequencing based on patient-specific pathways.
Related Resources & Content
